Design to come?

WP_Post Object
(
    [ID] => 1173
    [post_author] => 3
    [post_date] => 2022-05-03 11:36:22
    [post_date_gmt] => 2022-05-03 16:36:22
    [post_content] => 
    [post_title] => Intensity Therapeutics Announces New Clinical Data in Solid Tumors for its Lead Asset, INT230-6, Were Accepted for Two Poster Discussion Sessions and Three Poster Presentations at the Upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
    [post_excerpt] => 
    [post_status] => publish
    [comment_status] => closed
    [ping_status] => closed
    [post_password] => 
    [post_name] => intensity-therapeutics-announces-new-clinical-data-in-solid-tumors-for-its-lead-asset-int230-6-were-accepted-for-two-poster-discussion-sessions-and-three-poster-presentations-at-the-upcoming-2022-am
    [to_ping] => 
    [pinged] => 
    [post_modified] => 2022-05-10 11:37:03
    [post_modified_gmt] => 2022-05-10 16:37:03
    [post_content_filtered] => 
    [post_parent] => 0
    [guid] => https://vcapital.com/?post_type=news&p=1173
    [menu_order] => 0
    [post_type] => news
    [post_mime_type] => 
    [comment_count] => 0
    [filter] => raw
)